The anti-neprilysin market consists of drugs that inhibit neprilysin, a zinc metalloproteinase enzyme which degrades natriuretic peptides. Neprilysin inhibitor drugs are primarily used for the treatment of acute and chronic heart failure by preventing degradation of peptides like natriuretic peptides, which have beneficial cardiovascular effects. The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing prevalence of heart failure presents a major market opportunity for anti-neprilysin drugs. Heart failure affects over 26 million people globally and leads to significant healthcare costs and reduced quality of life. Currently, the only approved neprilysin inhibitor drug is Entresto, used for chronic heart failure. However, clinical trials are ongoing to expand approval of neprilysin inhibitors to other heart conditions and in combination with other heart drugs. As neprilysin inhibitors work through a novel mechanism compared to existing heart failure drugs, they are expected to witness increased adoption for treating various forms of heart failure over the forecast period. This rising incidence of heart failure combined with the unmet needs for more effective treatment options will likely drive higher demand for anti-neprilysin drugs going forward.
Porter's Analysis
Threat of new entrants: High capital requirements for R&D and clinical trials pose barriers to market entry. Bargaining power of buyers: Large pharmaceutical companies have significant buyer power to negotiate pricing. Bargaining power of suppliers: Suppliers of raw materials have moderate bargaining power due to availability of substitute materials. Threat of new substitutes: Emergence of novel treatment options presents threat of substitution. Competitive rivalry: Intense competition exists among existing players to develop new and improved therapies.
SWOT Analysis
Strengths: Strong pipeline of drugs in clinical trials. Unmet medical needs present market opportunities. Weaknesses: High R&D costs and regulatory hurdles. Safety concerns limit wider patient eligibility. Opportunities: Potential for new indications and combination therapies. Expanding elderly population increases patient base. Threats: Stringent regulatory environment. Reimbursement challenges in certain markets.
Key Takeaways
The global anti-neprilysin market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis shows Asia Pacific is likely to witness fastest growth owing to increasing patient awareness, rising healthcare expenditure, and improving research infrastructure in major countries like China and India.
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET leads the clinical research for novel neprilysin inhibitors while Novartis is conducting phase 2 trials of approved heart failure drug Entresto.